Terguride | CAS#37686-84-3 | 5-HT receptor antagonist

MedKoo Cat#: 463635 | Name: Terguride

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Terguride is 5-HT receptor antagonist. Terguride is a drug used to treat hyperprolactinemia that antagonizes 5-HT2A and 5-HT2B and activates dopamine receptors. It has also been extensively studied for the treatment of PAH.

Chemical Structure

Terguride

CAS#37686-84-3

Theoretical Analysis

MedKoo Cat#: 463635

Name: Terguride

CAS#: 37686-84-3

Chemical Formula: C20H28N4O

Exact Mass: 340.2263

Molecular Weight: 340.47

Elemental Analysis: C, 70.56; H, 8.29; N, 16.46; O, 4.70

Price and Availability

Size	Price	Availability
1mg	USD 350.00	2 Weeks
5mg	USD 750.00	2 Weeks
10mg	USD 1,150.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Terguride; Dironyl; trans-Dihydrolisuride; trans Dihydrolisuride;

IUPAC/Chemical Name

1,1-diethyl-3-((6aR,9S,10aR)-7-methyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl)urea

InChi Key

JOAHPSVPXZTVEP-YXJHDRRASA-N

InChi Code

InChI=1S/C20H28N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,11,14,16,18,21H,4-5,9-10,12H2,1-3H3,(H,22,25)/t14-,16+,18+/m0/s1

SMILES Code

[H][C@]12C[C@H](N([H])C(N(CC)CC)=O)CN(C)[C@]1([H])CC3=CN([H])C4=CC=CC2=C34

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 340.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Labad J, Montalvo I, González-Rodríguez A, García-Rizo C, Crespo-Facorro B, Monreal JA, Palao D. Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: A systematic review and meta-analysis. Schizophr Res. 2020 Aug;222:88-96. doi: 10.1016/j.schres.2020.04.031. Epub 2020 Jun 2. PMID: 32507371. 2: Alcántara-Vázquez O, Villamil-Hernández MT, Sánchez-López A, Pertz HH, Villalón CM, Centurión D. Blocking properties of terguride at the 5-HT2 receptor subtypes mediating cardiovascular responses in the rat. Can J Physiol Pharmacol. 2020 Aug;98(8):511-521. doi: 10.1139/cjpp-2019-0591. Epub 2020 Apr 8. PMID: 32268074. 3: Chaturvedi S, Misra DP, Prasad N, Rastogi K, Singh H, Rai MK, Agarwal V. 5-HT2 and 5-HT2B antagonists attenuate pro-fibrotic phenotype in human adult dermal fibroblasts by blocking TGF-β1 induced non- canonical signaling pathways including STAT3 : implications for fibrotic diseases like scleroderma. Int J Rheum Dis. 2018 Dec;21(12):2128-2138. doi: 10.1111/1756-185X.13386. Epub 2018 Sep 12. PMID: 30207074. 4: Gocht A, Distler JHW, Spriewald B, Ramsperger-Gleixner M, Weyand M, Ensminger SM, Heim C. Effects of different serotonin receptor subtype antagonists on the development of cardiac allograft vasculopathy in murine aortic allografts. Transpl Immunol. 2018 Aug;49:43-53. doi: 10.1016/j.trim.2018.04.002. Epub 2018 Apr 9. PMID: 29649585. 5: Tawfik MK, Makary S. 5-HT7 receptor antagonism (SB-269970) attenuates bleomycin-induced pulmonary fibrosis in rats via downregulating oxidative burden and inflammatory cascades and ameliorating collagen deposition: Comparison to terguride. Eur J Pharmacol. 2017 Nov 5;814:114-123. doi: 10.1016/j.ejphar.2017.08.014. Epub 2017 Aug 16. PMID: 28821451. 6: Thomsen M, Barrett AC, Butler P, Negus SS, Caine SB. Effects of Acute and Chronic Treatments with Dopamine D2 and D3 Receptor Ligands on Cocaine versus Food Choice in Rats. J Pharmacol Exp Ther. 2017 Jul;362(1):161-176. doi: 10.1124/jpet.117.241141. Epub 2017 May 4. PMID: 28473458; PMCID: PMC5469403. 7: Bruni C, Praino E, Allanore Y, Distler O, Gabrielli A, Iannone F, Matucci- Cerinic M. Use of biologics and other novel therapies for the treatment of systemic sclerosis. Expert Rev Clin Immunol. 2017 May;13(5):469-482. doi: 10.1080/1744666X.2017.1263153. Epub 2016 Dec 12. PMID: 27899043. 8: Elaidy SM, Essawy SS. The antifibrotic effects of alveolar macrophages 5-HT2C receptors blockade on bleomycin-induced pulmonary fibrosis in rats. Pharmacol Rep. 2016 Dec;68(6):1244-1253. doi: 10.1016/j.pharep.2016.08.005. Epub 2016 Aug 12. PMID: 27686964. 9: Lythgoe MP, Rhodes CJ, Ghataorhe P, Attard M, Wharton J, Wilkins MR. Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future. Pharmacol Ther. 2016 Aug;164:195-203. doi: 10.1016/j.pharmthera.2016.04.012. Epub 2016 Apr 29. PMID: 27133570. 10: Zajdel P, Bednarski M, Sapa J, Nowak G. Ergotamine and nicergoline - facts and myths. Pharmacol Rep. 2015 Apr;67(2):360-3. doi: 10.1016/j.pharep.2014.10.010. Epub 2014 Oct 30. PMID: 25712664. 11: Janssen W, Schymura Y, Novoyatleva T, Kojonazarov B, Boehm M, Wietelmann A, Luitel H, Murmann K, Krompiec DR, Tretyn A, Pullamsetti SS, Weissmann N, Seeger W, Ghofrani HA, Schermuly RT. 5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure. Biomed Res Int. 2015;2015:438403. doi: 10.1155/2015/438403. Epub 2015 Feb 1. PMID: 25667920; PMCID: PMC4312574. 12: Hashimoto K, Sugawara N, Ishioka M, Nakamura K, Yasui-Furukori N. The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study. Neuropsychiatr Dis Treat. 2014 Aug 22;10:1571-6. doi: 10.2147/NDT.S68298. PMID: 25187719; PMCID: PMC4149438. 13: Der-Ghazarian T, Widarma CB, Gutierrez A, Amodeo LR, Valentine JM, Humphrey DE, Gonzalez AE, Crawford CA, McDougall SA. Behavioral effects of dopamine receptor inactivation in the caudate-putamen of preweanling rats: role of the D2 receptor. Psychopharmacology (Berl). 2014 Feb;231(4):651-62. doi: 10.1007/s00213-013-3280-9. Epub 2013 Sep 22. PMID: 24057816; PMCID: PMC3946740. 14: Huang J, Gong Q, Huang C, Li G. Relationships between serotoninergic system and skin fibrotic. Antiinflamm Antiallergy Agents Med Chem. 2014 Mar;13(1):9-16. doi: 10.2174/18715230113129990018. PMID: 23909604. 15: Jantschak F, Brosda J, Franke RT, Fink H, Möller D, Hübner H, Gmeiner P, Pertz HH. Pharmacological profile of 2-bromoterguride at human dopamine D2, porcine serotonin 5-hydroxytryptamine 2A, and α2C-adrenergic receptors, and its antipsychotic-like effects in rats. J Pharmacol Exp Ther. 2013 Oct;347(1):57-68. doi: 10.1124/jpet.113.205997. Epub 2013 Jul 17. PMID: 23863695. 16: Sitbon O, Morrell N. Pathways in pulmonary arterial hypertension: the future is here. Eur Respir Rev. 2012 Dec 1;21(126):321-7. doi: 10.1183/09059180.00004812. PMID: 23204120. 17: Tadori Y, Kikuchi T. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors]. Nihon Shinkei Seishin Yakurigaku Zasshi. 2012 Feb;32(1):9-18. Japanese. PMID: 22568121. 18: Kekewska A, Görnemann T, Jantschak F, Glusa E, Pertz HH. Antiserotonergic properties of terguride in blood vessels, platelets, and valvular interstitial cells. J Pharmacol Exp Ther. 2012 Feb;340(2):369-76. doi: 10.1124/jpet.111.187906. Epub 2011 Nov 2. PMID: 22049464. 19: Antoniu SA. Terguride for pulmonary arterial hypertension. Expert Opin Ther Targets. 2011 Nov;15(11):1333-5. doi: 10.1517/14728222.2011.600692. Epub 2011 Jul 16. PMID: 21762037. 20: Steed E, Jones CA, McCreary AC. Serotonergic involvement in methamphetamine- induced locomotor activity: a detailed pharmacological study. Behav Brain Res. 2011 Jun 20;220(1):9-19. doi: 10.1016/j.bbr.2011.01.026. Epub 2011 Jan 22. PMID: 21262272.